Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HemaSure/Cobe

This article was originally published in The Gray Sheet

Executive Summary

Cobe Labs invests $9 mil. in blood filtration technology firm HemaSure in exchange for 4.5 mil. shares of HemaSure common stock, giving Cobe 30.2% of the company. Cobe also gains an option to purchase an additional $3 mil. in stock between Aug. 3, 1999 and May 3, 2000, and representation on HemaSure's board of directors and its representative committees. Proceeds will go toward U.S. commercialization of HemaSure's r/LS red blood cell filtration system, for which 510(k) clearance is expected by July. Cobe will distribute the device in the U.S. In conjunction with the financing, the two firms have signed an amended exclusive distribution agreement making Cobe the worldwide distributor of HemaSure products, excluding sales to the American Red Cross
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel